NCT06136585View on ClinicalTrials.gov

Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Neuromuscular Blocks
Interventions
DRUG

2 mg/kg sugammadex

All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 2 mg/kg sugammadex.

DRUG

0.07 mg/kg neostigmine

All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 0.07 mg/kg neostigmine (to a maximum of 5 mg).

Trial Locations (1)

44195

RECRUITING

Cleveland Clinic Foundation, Cleveland

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

The Cleveland Clinic

OTHER